• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Core One Labs Inc (OP: CLABF )

    0.1033 +0.0178 (+20.82%)
    Streaming Delayed Price Updated: 1:27 PM EST, Nov 11, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,508
    Open 0.1033
    Bid (Size) N/A (0)
    Ask (Size) N/A (0)
    Prev. Close 0.0855
    Today's Range 0.1033 - 0.1033
    52wk Range 0.0260 - 0.3500
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Core One Labs Inc. Announces Initial Agreement for Potential Sale of Proprietary Biosynthetic Psilocybin, Facilitating Entry into the International Market
    Via ACCESSWIRE
    Core One Labs’ Akome Reveals Impressive Results for its Psychedelic Bio-Compounds Designed to Target Alzheimer’s and Parkinson’s, Showing Potential to Outperform Current Treatment Methods
    Via ACCESSWIRE

    Performance

    YTD
    -51.84%
    -51.84%
    1 Month
    +21.10%
    +21.10%
    3 Month
    -0.10%
    -0.10%
    6 Month
    -40.25%
    -40.25%
    1 Year
    -34.74%
    -34.74%

    More News

    Read More
    Core One's Akome Reveals Groundbreaking Positive Results from its Second Round of Stage 1 Animal Model Studies for Bio-Compounds Targeting Alzheimer’s and Parkinson's Disease
    Via ACCESSWIRE
    Core One Labs', Awakened Biosciences, Announces Groundbreaking Step Forward in Isolating and Purifying Psilocybin from Mushroom Biomass
    Via ACCESSWIRE
    Core One's Akome Receives Positive Preliminary Stage 1 Animal Model Study Results for Bio-Compound Targeting Alzheimer’s and Parkinson’s Disease
    Via ACCESSWIRE
    Psyched: Germany Ships LSD Prodrugs Via DHL, Minneapolis Decriminalizes, Wiz Khalifa's Magic Pitch & More
    Via Benzinga
    Core One Labs Enters Into LOI For First Sale Of Its Psychedelic Compounds
    Via Benzinga
    Core One's Vocan Biotechnologies Incorporates New Bioreactor Equipment into Production Process Significantly Increasing Throughput of Proprietary Biosynthetic Psilocybin
    Via ACCESSWIRE
    Core One's Vocan Files International Patent for its Breakthrough Proprietary Biosynthetic Psilocybin Production Method
    Via ACCESSWIRE
    Core One in Talks with Multiple Companies to Supply Psilocybin
    Via ACCESSWIRE
    Core One Labs' GMP Drug Takes Further Steps Toward Commercialization: Initiating Development of Psychedelic Prodrugs with Long-established Compounding Pharmacy
    Via ACCESSWIRE
    Core One's Awakened Lays The Groundwork For The Large-Scale Production Of Psychedelic Compounds With Synthetic Production Of Psilocin
    Via Benzinga
    Core One's Awakened Completes Successful Synthetic Production of Psilocin in its GMP Certified Manufacturing Facility
    Via ACCESSWIRE
    Across The Globe: Psychedelic Trials To Treat Late-Stage Cancer, Alzheimer's Begin
    Via Benzinga
    Psyched: States With Psychedelics Legalization Bills, Next-Gen Molecule For Addiction Treatment And More
    Via Benzinga
    Core One Labs' Akome Signs Contract with University of Barcelona: Initiating Animal Model Studies on Psychedelics Drug Development to Combat a Variety of Neurological Diseases
    Via ACCESSWIRE
    Here Are The Latest Psychedelics Partnerships From Production & Supply Chain To Community Action
    Via Benzinga
    Core One Labs' Acquires GMP Drug Inc.: Positioning Itself as a Full Cycle Psychedelics Supply Chain Solution for Clinicians, Researchers and Other Drug Developers
    Via ACCESSWIRE
    Psyched: Canada's Psychedelic Therapy Guidelines, $39M Series B For Next-Gen Drugs, Mexico's Ancestral Roots & More
    Via Benzinga
    Psychedelic Mushrooms Soon To Be Commercially Produced And Sold In Canada
    Via Benzinga
    Core One Labs’ Prepares for Commercial Production of API-Grade Psilocybin; Plans Initial Production Run at GMP Facility in January
    Via ACCESSWIRE
    Core One Labs Takes Next Steps to Prepare for Potential Takeover Opportunities
    Via ACCESSWIRE
    European University to Fund Core One Labs' Akome Advanced Neurogenesis Stimulation Studies
    Via ACCESSWIRE
    Core One Labs Nearing GMP Production as Canada’s Province of Alberta Announces Game Changing Legislation
    Via ACCESSWIRE
    Core One Labs Announces Breakthrough with Proprietary Isolation and Purification Method of Psilocybin from Mushrooms; Prepares Patent Application
    Via ACCESSWIRE
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.